Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Communications, 1(11), 2020

DOI: 10.1038/s41467-020-19568-1

Links

Tools

Export citation

Search in Google Scholar

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Journal article published in 2020 by Shuang Wang, Yun Peng, Rongjuan Wang, Shasha Jiao, Min Wang, Weijin Huang ORCID, Chao Shan ORCID, Wen Jiang, Zepeng Li, Chunying Gu, Ben Chen, Xue Hu, Yanfeng Yao, Juan Min, Huajun Zhang and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractEfficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.